Viatris has agreed to acquire Pacira BioSciences for $1.65 billion in cash.
The deal values Pacira at $36.50 per share and is expected to close by the end of 2026. The acquisition adds non-opioid pain therapies to Viatrisโ innovative medicines portfolio and is anticipated to be immediately accretive.
#VTRS #PCRX #Pharma #CoinVahini #Healthcare
The deal values Pacira at $36.50 per share and is expected to close by the end of 2026. The acquisition adds non-opioid pain therapies to Viatrisโ innovative medicines portfolio and is anticipated to be immediately accretive.
#VTRS #PCRX #Pharma #CoinVahini #Healthcare